MoonLake Immunotherapeutics: Shareholder Legal Action Update

MoonLake Immunotherapeutics Faces Class Action Lawsuit

The Law Offices of Frank R. Cruz has recently announced that a class action lawsuit has been initiated on behalf of shareholders who invested in MoonLake Immunotherapeutics (NASDAQ: MLTX). This action pertains to individuals who acquired common stock between March 10, 2024, and September 29, 2025. Shareholders have a deadline to file a lead plaintiff motion by December 15, 2025.

Understanding the Legal Background

This lawsuit is significant for investors, especially those who may have suffered losses due to recent financial disclosures. The law firm encourages any affected shareholder to inquire about their rights and participate in this collective legal effort. If you experienced financial setbacks related to your investment in MoonLake Immunotherapeutics, reaching out to legal representatives may provide avenues for recovery.

What Triggered the Lawsuit?

The catalyst for this class action was an announcement by MoonLake Immunotherapeutics regarding disappointing results from its Phase 3 trials for its primary drug candidate, sonelokimab (SLK). On September 28, 2025, the company disclosed that SLK failed to achieve the efficacy benchmarks set by its competitor, Union Chimique Belge's bimekizumab-bkz (BIMZELX). This revelation was particularly alarming as the company had touted SLK's unique nanobody structure as a superior option. However, it became apparent that SLK targeted the same inflammatory cytokines and had no proven clinical advantages over existing treatments.

Impact on Shareholder Value

Following the announcement of the trial results, the market reacted sharply. MoonLake's stock plummeted by an astounding $55.74, which is a staggering 89.9% decline, leaving the stock price at just $6.24 per share by September 29, 2025. Such a dramatic drop undoubtedly harmed investors and raised questions about the company's prior disclosures.

Lawsuit Details and Allegations

The class action complaint alleges that throughout the specified Class Period, the defendants engaged in misleading practices by making false statements and failing to reveal crucial adverse facts regarding the company's business performance and future prospects. Key allegations include a lack of disclosure about the similarities between SLK and BIMZELX, concerns about SLK's clinical efficacy, and a rise in misleading positive statements regarding the company’s operations.

Take Action: Your Rights as an Investor

If you are a shareholder of MoonLake Immunotherapeutics and wish to comprehend your rights or learn more about this ongoing class action, consider reaching out to legal professionals. The Law Offices of Frank R. Cruz offer a pathway for interested parties to understand the implications of the lawsuit and the steps they can take.

Contact Information

For further inquiries or to explore your participation in the class action, you can reach out via email or telephone. Contact the Law Offices of Frank R. Cruz by emailing info@frankcruzlaw.com or calling (310) 914-5007. You can also visit the firm’s website for more details and resources.

Frequently Asked Questions

What is the class action lawsuit regarding MoonLake Immunotherapeutics?

The class action lawsuit concerns disclosures related to MoonLake's Phase 3 trial results for sonelokimab and potential damages incurred by shareholders.

Who can participate in the lawsuit?

Shareholders who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible to participate in the class action.

What happened to MoonLake's stock?

Following disappointing trial results announced on September 28, 2025, MoonLake's stock fell dramatically by nearly 90% the next day.

How can I claim participation in the lawsuit?

Interested shareholders should contact the Law Offices of Frank R. Cruz to learn about their rights and how to file claims.

What is the deadline for claims?

The deadline for filing a lead plaintiff motion is December 15, 2025.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.